Relationship between ALZpath pTau217 and cognitive test performance in a primary care sample

Abstract Background Blood biomarkers are a promising tool for identifying Alzheimer's disease (AD), particularly in primary care settings where AD and related dementias are frequently undiagnosed. More information in real‐world clinical cohorts is needed to increase confidence in the utility of plasma biomarkers, particularly phosphorylated tau at threonine 217 (pTau217), which has demonstrated reliability in indicating AD pathology (Devanarayan V, et al., 2024) and strong correlations with positive amyloid PET scans (Ashton N, et al., 2023). This study aimed to examine the relationship of plasma pTau217 to cognitive test performance in a real‐world primary care cohort. Method Sixty‐eight older adults completed the Quick Mild Cognitive Impairment (Qmci) screen during a routine primary care visit and a blood draw on the same day or within six weeks. Participants with elevated ALZpath pTau217 levels (> 0.63 ng/L) were classified as positive, and those with pTau217 levels between 0.34‐0.63 ng/L were classified as intermediate (Mammel AE, et al., 2025). A subset of participants ( n = 58) completed a neuropsychological test battery (NTB) consisting of language, memory, and executive functioning (EF) measures. Participants were considered cognitively impaired if they had two or more demographically adjusted T scores < 40 within the language, memory, or EF domains or one demographically adjusted T score < 40 in each of the three domains. Result Average age was 68.8 years (69% female, 90% White), and 26% were APOEε4. Five participants (7%) had positive pTau217 levels, and 15 (22%) had intermediate levels. Of the five pTau217 positive participants, none were cognitively impaired on the Qmci, but three were cognitively impaired on the NTB, two in the memory domain and one in memory and EF. Of the 15 with intermediate pTau217 levels, two were impaired on the Qmci and four were impaired on the NTB, all in the memory domain only. Higher average concentrations of pTau217 correlated significantly with lower composite memory T scores ( r = ‐.26; p = 05) but not global, language, or EF T scores. Conclusion Elevated levels of pTau217 were relatively low in this generally cognitively intact primary care cohort, but showed adequate concordance with cognitive performance, especially memory.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70856_107422
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Relationship between ALZpath pTau217 and cognitive test performance in a primary care sample

Lee Honigberg, Scott Selinger, L Guadagno, Robin C. Hilsabeck et al.
Alzheimer s & Dementia
Dementia and Cognitive Impairment Research
article

Relationship between ALZpath pTau217 and cognitive test performance in a primary care sample

Lee Honigberg, Scott Selinger, L Guadagno, Robin C. Hilsabeck, Andreas Jeromin, Carolynne C. Holbrook, Heather E. Cuevas, Joshua T Chang, Donald Biehl, Nusha Kheradbin, Claire Harrison, Teodora Stoica, Tomequa Sears, Michael Metke, Ryan Huebinger, Ling‐Yu Chang
article en

Abstract

Abstract Background Blood biomarkers are a promising tool for identifying Alzheimer's disease (AD), particularly in primary care settings where AD and related dementias are frequently undiagnosed. More information in real‐world clinical cohorts is needed to increase confidence in the utility of plasma biomarkers, particularly phosphorylated tau at threonine 217 (pTau217), which has demonstrated reliability in indicating AD pathology (Devanarayan V, et al., 2024) and strong correlations with positive amyloid PET scans (Ashton N, et al., 2023). This study aimed to examine the relationship of plasma pTau217 to cognitive test performance in a real‐world primary care cohort. Method Sixty‐eight older adults completed the Quick Mild Cognitive Impairment (Qmci) screen during a routine primary care visit and a blood draw on the same day or within six weeks. Participants with elevated ALZpath pTau217 levels (> 0.63 ng/L) were classified as positive, and those with pTau217 levels between 0.34‐0.63 ng/L were classified as intermediate (Mammel AE, et al., 2025). A subset of participants ( n = 58) completed a neuropsychological test battery (NTB) consisting of language, memory, and executive functioning (EF) measures. Participants were considered cognitively impaired if they had two or more demographically adjusted T scores < 40 within the language, memory, or EF domains or one demographically adjusted T score < 40 in each of the three domains. Result Average age was 68.8 years (69% female, 90% White), and 26% were APOEε4. Five participants (7%) had positive pTau217 levels, and 15 (22%) had intermediate levels. Of the five pTau217 positive participants, none were cognitively impaired on the Qmci, but three were cognitively impaired on the NTB, two in the memory domain and one in memory and EF. Of the 15 with intermediate pTau217 levels, two were impaired on the Qmci and four were impaired on the NTB, all in the memory domain only. Higher average concentrations of pTau217 correlated significantly with lower composite memory T scores ( r = ‐.26; p = 05) but not global, language, or EF T scores. Conclusion Elevated levels of pTau217 were relatively low in this generally cognitively intact primary care cohort, but showed adequate concordance with cognitive performance, especially memory.

Alzheimer s & DementiaVol. 21(S2)
The University of Texas at San Antonio Health Science Center (US), Structural Analytics (United States) (US), Banyan Biomarkers (United States) (US), Western Washington University (US), The University of Texas at Austin (US), The University of Texas Southwestern Medical Center (US), The University of Texas Health Science Center at Houston (US)
Openalex Percentile: Top 29%
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.